Display Settings:

Format

Send to:

Choose Destination
    Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):316-20.

    New insights into cancer-associated thrombosis.

    Source

    James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA.

    Abstract

    Venous thromboembolism (VTE) is an increasingly frequent complication of anticancer therapy. The underlying mechanisms are not completely understood, but are related in part to oncogene activation and tissue factor (TF) expression. Several risk factors have been identified including site and stage of cancer, patient comorbidities, and specific therapeutic agents. Candidate biomarkers such as blood counts, TF, and P-selectin have recently been identified. A risk model predictive of chemotherapy-associated VTE has been validated. Thromboprophylaxis with low molecular weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux is recommended for hospitalized medical and surgical cancer patients. Long-term anticoagulation with LMWH is safe and effective in reducing recurrent VTE in cancer. The role of thromboprophylaxis in ambulatory cancer patients receiving chemotherapy is an area of active investigation.

    PMID:
    19228604
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2727713
    Free PMC Article

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk